Interventional oncology Market- Global Industry Analysis and Forecast (2022-2029)

Interventional oncology Market is expected to grow at a CAGR of 7.9% during the forecast period and the market size is expected to reach nearly US$ 3.77 Bn by 2029.

Interventional oncology Market Product Definition

Interventional oncology is a subspecialty area of interventional radiology that offers with the diagnosis and treatment of most cancers and most cancers-related problems using focused minimally invasive tactics achieved underneath image guidance.Global Interventional oncology MarketTo know about the Research Methodology :- Request Free Sample Report (The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.)

Interventional oncology Market Dynamics

Interventional oncology has evolved into a separate pillar of cutting-edge oncology and it employs X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to help guide miniaturized contraptions to permit focused and precise treatment of solid tumors positioned in various organs of the human body. Interventional oncology procedures are usually divided among diagnostic strategies that help obtain tissue diagnosis of suspicious neoplasms and therapeutic ones that goal to cure therapy or palliate the tumor. Both ablation and embolization techniques are minimally invasive treatments. The worldwide interventional oncology market is ordinarily compelled with the aid of excessive occurrence and upsurge in the prevalence rates of most cancers worldwide. Cancer is the second one main cause of death globally, accounting for an expected 9.6 million deaths, or one in six deaths, in 2018. According to GLOBOCAN, in 2018 here will be an estimated 18.1 million new cancer cases and 9.6 million cancer deaths in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Benefits of minimally invasive surgical methods, technological improvements in interventional oncology, expanded authorities funding for oncology procedures etc. are projected to boost the growth of the interventional oncology market throughout the forecast duration. Every month within the United States, more than 1.6 million people are diagnosed with most cancers, and approximately 600,000 die from it. The value of most cancers care maintains to upward thrust and is predicted to reach almost US$174 billion by way of 2021.

Interventional oncology Market Segment analysis

Based at the Product, the tumor embolization procedures segment is projected to grow at a CAGR of xx% for the duration of the forecast duration. Tumor embolization procedures commanded the largest share of the worldwide interventional oncology market in 2021 mainly because of their wide utilization with high sensitivity, specificity, and accuracy in the direction of the detection and characterization of tumors. Furthermore, the improvements in embolization techniques together with studies applications for the improvement of yttrium 90 isotopes efficiency have brought about a growth in demand for embolization procedures worldwide.

Interventional oncology Market Regional analysis

North America is anticipated to dominate the worldwide interventional oncology market throughout the estimate period. For the main share of the global interventional oncology market owing to a large populace base troubled with chronic cancer. Additionally substantial acceptance of minimally invasive surgical procedures for the influential management of cancer, well-set-up health care infrastructure, and early acceptance of technically progressive interventional oncology products etc. are factors that can be probable to impel the growth of the interventional oncology market during the forecast period. Besides, the U.S. most cancers care expenditure was $50 billion in 2017. In forthcoming, costs are possible to upsurge as the populace ages and most cancers incidences increases. Thus, factors consisting of growing cancer prevalence, growing most cancers-related healthcare expenditure, and demand for advanced cancer care alternatives are propelling the adoption of interventional oncology. The interventional oncology market in the Asia Pacific is expected to increase at a high CAGR during the estimate duration due to high incidence of cancer in the highly populous countries of India and China, rapidly converting health care systems, numerous authorities’ initiatives to improve usual health care, and elevated in keeping with capita health care expenditure. The objective of the report is to present a comprehensive analysis of the Global Interventional oncology Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Interventional oncology Market dynamics, structure by analysing the market segments and projects the Global Interventional oncology Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Interventional oncology Market make the report investor’s guide.

Scope of the Global Interventional oncology Market: Inquire before buying

Global Interventional oncology Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 2.05 Bn.
Forecast Period 2022 to 2029 CAGR: 7.9% Market Size in 2029: US $ 3.77 Bn.
Segments Covered: by Procedure • Ablation Devices • Embolization Devices • Micro catheters • Guide wires • Others
by Product • Tumor Embolization • Radioembolic agents • Non-radioactive embolic agents • Tumor Ablation
by Cancer Type • Lung cancer • Breast Cancer • Liver Cancer • Kidney Cancer • Prostate Cancer • Others

Interventional oncology Market, by Regions

• North America • Europe • Asia-Pacific • South America • Middle East and Africa (MEA)

Interventional oncology Market Key Players are:

Boston Scientific • BTG • Medtronic • Merit Medical • Terumo • Accuray • Alpinion Medical Systems • Angiodynamics • Atricure • Baylis Medical • Bovie Medical • Brainlab • Bsd Medical • C. R. Bard • C2 Therapeutics • Cardiofocus • Cook Medical • Eckert And Ziegler Bebig • Edap Tms • Elekta • Galil Medical • Healthtronics Frequently Asked questions 1. What is the market size of the Global Interventional oncology Market in 2021? Ans. The market size Global Interventional oncology Market in 2021 was US$ 2.05 Billion. 2. What are the different segments of the Global Interventional oncology Market? Ans. The Global Interventional oncology Market  is divided into Product, Procedure and Cancer Type. 3. What is the study period of this market? Ans. The Global Interventional oncology Market will be studied from 2021 to 2029. 4. Which region is expected to hold the highest Global Interventional oncology Market share? Ans. The Asia Pacific dominates the market share in the  market. 5. What  is the Forecast Period of Global Interventional oncology Market? Ans. The Forecast Period of the market is 2022-2029 in the market.
Global Interventional oncology Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Tracheostomy Tubes Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Interventional Oncology Market Analysis and Forecast 6.1. Global Interventional Oncology Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Interventional Oncology Market Analysis and Forecast, By Procedure 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Interventional Oncology Market Value Share Analysis, By Procedure 7.4. Global Interventional Oncology Market Size (US$ Mn) Forecast, By Procedure 7.5. Global Interventional Oncology Market Analysis, By Procedure 7.6. Global Interventional Oncology Market Attractiveness Analysis, By Procedure 8. Global Interventional Oncology Market Analysis and Forecast, By Product 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Interventional Oncology Market Value Share Analysis, By Product 8.4. Global Interventional Oncology Market Size (US$ Mn) Forecast, By Product 8.5. Global Interventional Oncology Market Analysis, By Product 8.6. Global Interventional Oncology Market Attractiveness Analysis, By Product 9. Global Interventional Oncology Market Analysis and Forecast, By Cancer Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Interventional Oncology Market Value Share Analysis, By Cancer Type 9.4. Global Interventional Oncology Market Size (US$ Mn) Forecast, By Cancer Type 9.5. Global Interventional Oncology Market Analysis, By Cancer Type 9.6. Global Interventional Oncology Market Attractiveness Analysis, By Cancer Type 10. Global Interventional Oncology Market Analysis, by Region 10.1. Global Interventional Oncology Market Value Share Analysis, by Region 10.2. Global Interventional Oncology Market Size (US$ Mn) Forecast, by Region 10.3. Global Interventional Oncology Market Attractiveness Analysis, by Region 11. North America Interventional Oncology Market Analysis 11.1. Key Findings 11.2. North America Interventional Oncology Market Overview 11.3. North America Interventional Oncology Market Value Share Analysis, By Procedure 11.4. North America Interventional Oncology Market Forecast, By Procedure 11.4.1. Ablation Devices 11.4.1.1. Microwave ablation 11.4.1.2. Radiofrequency ablation 11.4.1.3. Cryoablation 11.4.1.4. Others 11.4.2. Embolization Devices 11.4.3. Micro catheters 11.4.4. Guide wires 11.4.5. Others 11.5. North America Interventional Oncology Market Value Share Analysis, By Product 11.6. North America Interventional Oncology Market Forecast, By Product 11.6.1. Tumor Embolization 11.6.1.1. Radioembolic agents 11.6.1.2. Non-radioactive embolic agents 11.6.1.3. Tumor Ablation 11.7. North America Interventional Oncology Market Value Share Analysis, By Cancer Type 11.8. North America Interventional Oncology Market Forecast, By Cancer Type 11.8.1. Lung cancer 11.8.2. Breast Cancer 11.8.3. Liver Cancer 11.8.4. Kidney Cancer 11.8.5. Prostate Cancer 11.8.6. Others 11.9. North America Interventional Oncology Market Value Share Analysis, by Country 11.10. North America Interventional Oncology Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Interventional Oncology Market Analysis, by Country 11.12. U.S. Interventional Oncology Market Forecast, By Procedure 11.12.1. Ablation Devices 11.12.1.1. Microwave ablation 11.12.1.2. Radiofrequency ablation 11.12.1.3. Cryoablation 11.12.1.4. Others 11.12.2. Embolization Devices 11.12.3. Micro catheters 11.12.4. Guide wires 11.12.5. Others 11.13. U.S. Interventional Oncology Market Forecast, By Product 11.13.1. Tumor Embolization 11.13.1.1. Radioembolic agents 11.13.1.2. Non-radioactive embolic agents 11.13.1.3. Tumor Ablation 11.14. U.S. Interventional Oncology Market Forecast, By Cancer Type 11.14.1. Lung cancer 11.14.2. Breast Cancer 11.14.3. Liver Cancer 11.14.4. Kidney Cancer 11.14.5. Prostate Cancer 11.14.6. Others 11.15. Canada Interventional Oncology Market Forecast, By Procedure 11.15.1. Ablation Devices 11.15.1.1. Microwave ablation 11.15.1.2. Radiofrequency ablation 11.15.1.3. Cryoablation 11.15.1.4. Others 11.15.2. Embolization Devices 11.15.3. Micro catheters 11.15.4. Guide wires 11.15.5. Others 11.16. Canada Interventional Oncology Market Forecast, By Product 11.16.1. Tumor Embolization 11.16.1.1. Radioembolic agents 11.16.1.2. Non-radioactive embolic agents 11.16.1.3. Tumor Ablation 11.17. Canada Interventional Oncology Market Forecast, By Cancer Type 11.17.1. Lung cancer 11.17.2. Breast Cancer 11.17.3. Liver Cancer 11.17.4. Kidney Cancer 11.17.5. Prostate Cancer 11.17.6. Others 11.18. North America Interventional Oncology Market Attractiveness Analysis 11.18.1. By Procedure 11.18.2. By Product 11.18.3. By Cancer Type 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Interventional Oncology Market Analysis 12.1. Key Findings 12.2. Europe Interventional Oncology Market Overview 12.3. Europe Interventional Oncology Market Value Share Analysis, By Procedure 12.4. Europe Interventional Oncology Market Forecast, By Procedure 12.4.1. Ablation Devices 12.4.1.1. Microwave ablation 12.4.1.2. Radiofrequency ablation 12.4.1.3. Cryoablation 12.4.1.4. Others 12.4.2. Embolization Devices 12.4.3. Micro catheters 12.4.4. Guide wires 12.4.5. Others 12.5. Europe Interventional Oncology Market Value Share Analysis, By Product 12.6. Europe Interventional Oncology Market Forecast, By Product 12.6.1. Tumor Embolization 12.6.1.1. Radioembolic agents 12.6.1.2. Non-radioactive embolic agents 12.6.1.3. Tumor Ablation 12.7. Europe Interventional Oncology Market Value Share Analysis, By Cancer Type 12.8. Europe Interventional Oncology Market Forecast, By Cancer Type 12.8.1. Lung cancer 12.8.2. Breast Cancer 12.8.3. Liver Cancer 12.8.4. Kidney Cancer 12.8.5. Prostate Cancer 12.8.6. Others 12.9. Europe Interventional Oncology Market Value Share Analysis, by Country 12.10. Europe Interventional Oncology Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Interventional Oncology Market Analysis, by Country 12.12. Germany Interventional Oncology Market Forecast, By Procedure 12.12.1. Ablation Devices 12.12.1.1. Microwave ablation 12.12.1.2. Radiofrequency ablation 12.12.1.3. Cryoablation 12.12.1.4. Others 12.12.2. Embolization Devices 12.12.3. Micro catheters 12.12.4. Guide wires 12.12.5. Others 12.13. Germany Interventional Oncology Market Forecast, By Product 12.13.1. Tumor Embolization 12.13.1.1. Radioembolic agents 12.13.1.2. Non-radioactive embolic agents 12.13.1.3. Tumor Ablation 12.14. Germany Interventional Oncology Market Forecast, By Cancer Type 12.14.1. Lung cancer 12.14.2. Breast Cancer 12.14.3. Liver Cancer 12.14.4. Kidney Cancer 12.14.5. Prostate Cancer 12.14.6. Others 12.15. U.K. Interventional Oncology Market Forecast, By Procedure 12.15.1. Ablation Devices 12.15.1.1. Microwave ablation 12.15.1.2. Radiofrequency ablation 12.15.1.3. Cryoablation 12.15.1.4. Others 12.15.2. Embolization Devices 12.15.3. Micro catheters 12.15.4. Guide wires 12.15.5. Others 12.16. U.K. Interventional Oncology Market Forecast, By Product 12.16.1. Tumor Embolization 12.16.1.1. Radioembolic agents 12.16.1.2. Non-radioactive embolic agents 12.16.1.3. Tumor Ablation 12.17. U.K. Interventional Oncology Market Forecast, By Cancer Type 12.17.1. Lung cancer 12.17.2. Breast Cancer 12.17.3. Liver Cancer 12.17.4. Kidney Cancer 12.17.5. Prostate Cancer 12.17.6. Others 12.18. France Interventional Oncology Market Forecast, By Procedure 12.18.1. Ablation Devices 12.18.1.1. Microwave ablation 12.18.1.2. Radiofrequency ablation 12.18.1.3. Cryoablation 12.18.1.4. Others 12.18.2. Embolization Devices 12.18.3. Micro catheters 12.18.4. Guide wires 12.18.5. Others 12.19. France Interventional Oncology Market Forecast, By Product 12.19.1. Tumor Embolization 12.19.1.1. Radioembolic agents 12.19.1.2. Non-radioactive embolic agents 12.19.1.3. Tumor Ablation 12.20. France Interventional Oncology Market Forecast, By Cancer Type 12.20.1. Lung cancer 12.20.2. Breast Cancer 12.20.3. Liver Cancer 12.20.4. Kidney Cancer 12.20.5. Prostate Cancer 12.20.6. Others 12.21. Italy Interventional Oncology Market Forecast, By Procedure 12.21.1. Ablation Devices 12.21.1.1. Microwave ablation 12.21.1.2. Radiofrequency ablation 12.21.1.3. Cryoablation 12.21.1.4. Others 12.21.2. Embolization Devices 12.21.3. Micro catheters 12.21.4. Guide wires 12.21.5. Others 12.22. Italy Interventional Oncology Market Forecast, By Product 12.22.1. Tumor Embolization 12.22.1.1. Radioembolic agents 12.22.1.2. Non-radioactive embolic agents 12.22.1.3. Tumor Ablation 12.23. Italy Interventional Oncology Market Forecast, By Cancer Type 12.23.1. Lung cancer 12.23.2. Breast Cancer 12.23.3. Liver Cancer 12.23.4. Kidney Cancer 12.23.5. Prostate Cancer 12.23.6. Others 12.24. Spain Interventional Oncology Market Forecast, By Procedure 12.24.1. Ablation Devices 12.24.1.1. Microwave ablation 12.24.1.2. Radiofrequency ablation 12.24.1.3. Cryoablation 12.24.1.4. Others 12.24.2. Embolization Devices 12.24.3. Micro catheters 12.24.4. Guide wires 12.24.5. Others 12.25. Spain Interventional Oncology Market Forecast, By Product 12.25.1. Tumor Embolization 12.25.1.1. Radioembolic agents 12.25.1.2. Non-radioactive embolic agents 12.25.1.3. Tumor Ablation 12.26. Spain Interventional Oncology Market Forecast, By Cancer Type 12.26.1. Lung cancer 12.26.2. Breast Cancer 12.26.3. Liver Cancer 12.26.4. Kidney Cancer 12.26.5. Prostate Cancer 12.26.6. Others 12.27. Rest of Europe Interventional Oncology Market Forecast, By Procedure 12.27.1. Ablation Devices 12.27.1.1. Microwave ablation 12.27.1.2. Radiofrequency ablation 12.27.1.3. Cryoablation 12.27.1.4. Others 12.27.2. Embolization Devices 12.27.3. Micro catheters 12.27.4. Guide wires 12.27.5. Others 12.28. Rest of Europe Interventional Oncology Market Forecast, By Product 12.28.1. Tumor Embolization 12.28.1.1. Radioembolic agents 12.28.1.2. Non-radioactive embolic agents 12.28.1.3. Tumor Ablation 12.29. Rest Of Europe Interventional Oncology Market Forecast, By Cancer Type 12.29.1. Lung cancer 12.29.2. Breast Cancer 12.29.3. Liver Cancer 12.29.4. Kidney Cancer 12.29.5. Prostate Cancer 12.29.6. Others 12.30. Europe Interventional Oncology Market Attractiveness Analysis 12.30.1. By Procedure 12.30.2. By Product 12.30.3. By Cancer Type 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Interventional Oncology Market Analysis 13.1. Key Findings 13.2. Asia Pacific Interventional Oncology Market Overview 13.3. Asia Pacific Interventional Oncology Market Value Share Analysis, By Procedure 13.4. Asia Pacific Interventional Oncology Market Forecast, By Procedure 13.4.1. Ablation Devices 13.4.1.1. Microwave ablation 13.4.1.2. Radiofrequency ablation 13.4.1.3. Cryoablation 13.4.1.4. Others 13.4.2. Embolization Devices 13.4.3. Micro catheters 13.4.4. Guide wires 13.4.5. Others 13.5. Asia Pacific Interventional Oncology Market Value Share Analysis, By Product 13.6. Asia Pacific Interventional Oncology Market Forecast, By Product 13.6.1. Tumor Embolization 13.6.1.1. Radioembolic agents 13.6.1.2. Non-radioactive embolic agents 13.6.1.3. Tumor Ablation 13.7. Asia Pacific Interventional Oncology Market Value Share Analysis, By Cancer Type 13.8. Asia Pacific Interventional Oncology Market Forecast, By Cancer Type 13.8.1. Lung cancer 13.8.2. Breast Cancer 13.8.3. Liver Cancer 13.8.4. Kidney Cancer 13.8.5. Prostate Cancer 13.8.6. Others 13.9. Asia Pacific Interventional Oncology Market Value Share Analysis, by Country 13.10. Asia Pacific Interventional Oncology Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Interventional Oncology Market Analysis, by Country 13.12. China Interventional Oncology Market Forecast, By Procedure 13.12.1. Ablation Devices 13.12.1.1. Microwave ablation 13.12.1.2. Radiofrequency ablation 13.12.1.3. Cryoablation 13.12.1.4. Others 13.12.2. Embolization Devices 13.12.3. Micro catheters 13.12.4. Guide wires 13.12.5. Others 13.13. China Interventional Oncology Market Forecast, By Product 13.13.1. Tumor Embolization 13.13.1.1. Radioembolic agents 13.13.1.2. Non-radioactive embolic agents 13.13.1.3. Tumor Ablation 13.14. China Interventional Oncology Market Forecast, By Cancer Type 13.14.1. Lung cancer 13.14.2. Breast Cancer 13.14.3. Liver Cancer 13.14.4. Kidney Cancer 13.14.5. Prostate Cancer 13.14.6. Others 13.15. India Interventional Oncology Market Forecast, By Procedure 13.15.1. Ablation Devices 13.15.1.1. Microwave ablation 13.15.1.2. Radiofrequency ablation 13.15.1.3. Cryoablation 13.15.1.4. Others 13.15.2. Embolization Devices 13.15.3. Micro catheters 13.15.4. Guide wires 13.15.5. Others 13.16. India Interventional Oncology Market Forecast, By Product 13.16.1. Tumor Embolization 13.16.1.1. Radioembolic agents 13.16.1.2. Non-radioactive embolic agents 13.16.1.3. Tumor Ablation 13.17. India Interventional Oncology Market Forecast, By Cancer Type 13.17.1. Lung cancer 13.17.2. Breast Cancer 13.17.3. Liver Cancer 13.17.4. Kidney Cancer 13.17.5. Prostate Cancer 13.17.6. Others 13.18. Japan Interventional Oncology Market Forecast, By Procedure 13.18.1. Ablation Devices 13.18.1.1. Microwave ablation 13.18.1.2. Radiofrequency ablation 13.18.1.3. Cryoablation 13.18.1.4. Others 13.18.2. Embolization Devices 13.18.3. Micro catheters 13.18.4. Guide wires 13.18.5. Others 13.19. Japan Interventional Oncology Market Forecast, By Product 13.19.1. Tumor Embolization 13.19.1.1. Radioembolic agents 13.19.1.2. Non-radioactive embolic agents 13.19.1.3. Tumor Ablation 13.20. Japan Interventional Oncology Market Forecast, By Cancer Type 13.20.1. Lung cancer 13.20.2. Breast Cancer 13.20.3. Liver Cancer 13.20.4. Kidney Cancer 13.20.5. Prostate Cancer 13.20.6. Others 13.21. ASEAN Interventional Oncology Market Forecast, By Procedure 13.21.1. Ablation Devices 13.21.1.1. Microwave ablation 13.21.1.2. Radiofrequency ablation 13.21.1.3. Cryoablation 13.21.1.4. Others 13.21.2. Embolization Devices 13.21.3. Micro catheters 13.21.4. Guide wires 13.21.5. Others 13.22. ASEAN Interventional Oncology Market Forecast, By Product 13.22.1. Tumor Embolization 13.22.1.1. Radioembolic agents 13.22.1.2. Non-radioactive embolic agents 13.22.1.3. Tumor Ablation 13.23. ASEAN Interventional Oncology Market Forecast, By Cancer Type 13.23.1. Lung cancer 13.23.2. Breast Cancer 13.23.3. Liver Cancer 13.23.4. Kidney Cancer 13.23.5. Prostate Cancer 13.23.6. Others 13.24. Rest of Asia Pacific Interventional Oncology Market Forecast, By Procedure 13.24.1. Ablation Devices 13.24.1.1. Microwave ablation 13.24.1.2. Radiofrequency ablation 13.24.1.3. Cryoablation 13.24.1.4. Others 13.24.2. Embolization Devices 13.24.3. Micro catheters 13.24.4. Guide wires 13.24.5. Others 13.25. Rest of Asia Pacific Interventional Oncology Market Forecast, By Product 13.25.1. Tumor Embolization 13.25.1.1. Radioembolic agents 13.25.1.2. Non-radioactive embolic agents 13.25.1.3. Tumor Ablation 13.26. Rest of Asia Pacific Interventional Oncology Market Forecast, By Cancer Type 13.26.1. Lung cancer 13.26.2. Breast Cancer 13.26.3. Liver Cancer 13.26.4. Kidney Cancer 13.26.5. Prostate Cancer 13.26.6. Others 13.27. Asia Pacific Interventional Oncology Market Attractiveness Analysis 13.27.1. By Procedure 13.27.2. By Product 13.27.3. By Cancer Type 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Interventional Oncology Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Interventional Oncology Market Overview 14.3. Middle East & Africa Interventional Oncology Market Value Share Analysis, By Procedure 14.4. Middle East & Africa Interventional Oncology Market Forecast, By Procedure 14.4.1. Ablation Devices 14.4.1.1. Microwave ablation 14.4.1.2. Radiofrequency ablation 14.4.1.3. Cryoablation 14.4.1.4. Others 14.4.2. Embolization Devices 14.4.3. Micro catheters 14.4.4. Guide wires 14.4.5. Others 14.5. Middle East & Africa Interventional Oncology Market Value Share Analysis, By Product 14.6. Middle East & Africa Interventional Oncology Market Forecast, By Product 14.6.1. Tumor Embolization 14.6.1.1. Radioembolic agents 14.6.1.2. Non-radioactive embolic agents 14.6.1.3. Tumor Ablation 14.7. Middle East & Africa Interventional Oncology Market Value Share Analysis, By Cancer Type 14.8. Middle East & Africa Interventional Oncology Market Forecast, By Cancer Type 14.8.1. Lung cancer 14.8.2. Breast Cancer 14.8.3. Liver Cancer 14.8.4. Kidney Cancer 14.8.5. Prostate Cancer 14.8.6. Others 14.9. Middle East & Africa Interventional Oncology Market Value Share Analysis, by Country 14.10. Middle East & Africa Interventional Oncology Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Interventional Oncology Market Analysis, by Country 14.12. GCC Interventional Oncology Market Forecast, By Procedure 14.12.1. Ablation Devices 14.12.1.1. Microwave ablation 14.12.1.2. Radiofrequency ablation 14.12.1.3. Cryoablation 14.12.1.4. Others 14.12.2. Embolization Devices 14.12.3. Micro catheters 14.12.4. Guide wires 14.12.5. Others 14.13. GCC Interventional Oncology Market Forecast, By Product 14.13.1. Tumor Embolization 14.13.1.1. Radioembolic agents 14.13.1.2. Non-radioactive embolic agents 14.13.1.3. Tumor Ablation 14.14. GCC Interventional Oncology Market Forecast, By Cancer Type 14.14.1. Lung cancer 14.14.2. Breast Cancer 14.14.3. Liver Cancer 14.14.4. Kidney Cancer 14.14.5. Prostate Cancer 14.14.6. Others 14.15. South Africa Interventional Oncology Market Forecast, By Procedure 14.15.1. Sprays 14.15.2. Drops & Liquids 14.15.3. Powders 14.15.4. Gels Ablation Devices 14.15.4.1. Microwave ablation 14.15.4.2. Radiofrequency ablation 14.15.4.3. Cryoablation 14.15.4.4. Others 14.15.5. Embolization Devices 14.15.6. Micro catheters 14.15.7. Guide wires 14.15.8. Others 14.16. South Africa Interventional Oncology Market Forecast, By Product 14.16.1. Tumor Embolization 14.16.1.1. Radioembolic agents 14.16.1.2. Non-radioactive embolic agents 14.16.1.3. Tumor Ablation 14.17. South Africa Interventional Oncology Market Forecast, By Cancer Type 14.17.1. Lung cancer 14.17.2. Breast Cancer 14.17.3. Liver Cancer 14.17.4. Kidney Cancer 14.17.5. Prostate Cancer 14.17.6. Others 14.18. Rest of Middle East & Africa Interventional Oncology Market Forecast, By Procedure 14.18.1. Ablation Devices 14.18.1.1. Microwave ablation 14.18.1.2. Radiofrequency ablation 14.18.1.3. Cryoablation 14.18.1.4. Others 14.18.2. Embolization Devices 14.18.3. Micro catheters 14.18.4. Guide wires 14.18.5. Others 14.19. Rest of Middle East & Africa Interventional Oncology Market Forecast, By Product 14.19.1. Tumor Embolization 14.19.1.1. Radioembolic agents 14.19.1.2. Non-radioactive embolic agents 14.19.1.3. Tumor Ablation 14.20. Rest of Middle East & Africa Interventional Oncology Market Forecast, By Cancer Type 14.20.1. Lung cancer 14.20.2. Breast Cancer 14.20.3. Liver Cancer 14.20.4. Kidney Cancer 14.20.5. Prostate Cancer 14.20.6. Others 14.21. Middle East & Africa Interventional Oncology Market Attractiveness Analysis 14.21.1. By Procedure 14.21.2. By Product 14.21.3. By Cancer Type 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Interventional Oncology Market Analysis 15.1. Key Findings 15.2. South America Interventional Oncology Market Overview 15.3. South America Interventional Oncology Market Value Share Analysis, By Procedure 15.4. South America Interventional Oncology Market Forecast, By Procedure 15.4.1. Ablation Devices 15.4.1.1. Microwave ablation 15.4.1.2. Radiofrequency ablation 15.4.1.3. Cryoablation 15.4.1.4. Others 15.4.2. Embolization Devices 15.4.3. Micro catheters 15.4.4. Guide wires 15.4.5. Others 15.5. South America Interventional Oncology Market Value Share Analysis, By Product 15.6. South America Interventional Oncology Market Forecast, By Product 15.6.1. Tumor Embolization 15.6.1.1. Radioembolic agents 15.6.1.2. Non-radioactive embolic agents 15.6.1.3. Tumor Ablation 15.7. South America Interventional Oncology Market Value Share Analysis, By Cancer Type 15.8. South America Interventional Oncology Market Forecast, By Cancer Type 15.8.1. Lung cancer 15.8.2. Breast Cancer 15.8.3. Liver Cancer 15.8.4. Kidney Cancer 15.8.5. Prostate Cancer 15.8.6. Others 15.9. South America Interventional Oncology Market Value Share Analysis, by Country 15.10. South America Interventional Oncology Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Interventional Oncology Market Analysis, by Country 15.12. Brazil Interventional Oncology Market Forecast, By Procedure 15.12.1. Ablation Devices 15.12.1.1. Microwave ablation 15.12.1.2. Radiofrequency ablation 15.12.1.3. Cryoablation 15.12.1.4. Others 15.12.2. Embolization Devices 15.12.3. Micro catheters 15.12.4. Guide wires 15.12.5. Others 15.13. Brazil Interventional Oncology Market Forecast, By Product 15.13.1. Tumor Embolization 15.13.1.1. Radioembolic agents 15.13.1.2. Non-radioactive embolic agents 15.13.1.3. Tumor Ablation 15.14. Brazil Interventional Oncology Market Forecast, By Cancer Type 15.14.1. Lung cancer 15.14.2. Breast Cancer 15.14.3. Liver Cancer 15.14.4. Kidney Cancer 15.14.5. Prostate Cancer 15.14.6. Others 15.15. Mexico Interventional Oncology Market Forecast, By Procedure 15.15.1. Ablation Devices 15.15.1.1. Microwave ablation 15.15.1.2. Radiofrequency ablation 15.15.1.3. Cryoablation 15.15.1.4. Others 15.15.2. Embolization Devices 15.15.3. Micro catheters 15.15.4. Guide wires 15.15.5. Others 15.16. Mexico Interventional Oncology Market Forecast, By Product 15.16.1. Tumor Embolization 15.16.1.1. Radioembolic agents 15.16.1.2. Non-radioactive embolic agents 15.16.1.3. Tumor Ablation 15.17. Mexico Interventional Oncology Market Forecast, By Cancer Type 15.17.1. Lung cancer 15.17.2. Breast Cancer 15.17.3. Liver Cancer 15.17.4. Kidney Cancer 15.17.5. Prostate Cancer 15.17.6. Others 15.18. Rest of South America Interventional Oncology Market Forecast, By Procedure 15.18.1. Ablation Devices 15.18.1.1. Microwave ablation 15.18.1.2. Radiofrequency ablation 15.18.1.3. Cryoablation 15.18.1.4. Others 15.18.2. Embolization Devices 15.18.3. Micro catheters 15.18.4. Guide wires 15.18.5. Others 15.19. Rest of South America Interventional Oncology Market Forecast, By Product 15.19.1. Tumor Embolization 15.19.1.1. Radioembolic agents 15.19.1.2. Non-radioactive embolic agents 15.19.1.3. Tumor Ablation 15.20. Rest of South America Interventional Oncology Market Forecast, By Cancer Type 15.20.1. Lung cancer 15.20.2. Breast Cancer 15.20.3. Liver Cancer 15.20.4. Kidney Cancer 15.20.5. Prostate Cancer 15.20.6. Others 15.21. South America Interventional Oncology Market Attractiveness Analysis 15.21.1. By Procedure 15.21.2. By Product 15.21.3. By Cancer Type 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Boston Scientific 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. BTG 16.3.3. Medtronic 16.3.4. Merit Medical 16.3.5. Terumo 16.3.6. Accuray 16.3.7. Alpinion Medical Systems 16.3.8. Angiodynamics 16.3.9. Atricure 16.3.10. Baylis Medical 16.3.11. Bovie Medical 16.3.12. Brainlab 16.3.13. Bsd Medical 16.3.14. C. R. Bard 16.3.15. C2 Therapeutics 16.3.16. Cardiofocus 16.3.17. Cook Medical 16.3.18. Eckert And Ziegler Bebig 16.3.19. Edap Tms 16.3.20. Elekta 16.3.21. Galil Medical 16.3.22. Healthtronics 17. Primary Key Insights

About This Report

Report ID 57766
Category Healthcare
Published Date Jan 2023
Updated Date
Contact Us